

DECISION LETTER FOR VACCINE SUPPORT

This Decision Letter sets out the Programme Terms

1. Country: Republic of Sierra Leone			
2. Vaccines Grant Number: 1314-SLE-19a-X Cash Support Grant Number: 1314-SLE-24a-Y			
3. Decision Letter no: 1			
4. Date of the Partnership Framework Agreement: Not applicable			
5. Programme Title: HPV Demonstration Programme			
6. Vaccine type: HPV			
7. Preferred product presentation and formulation of vaccine: HPV bivalent, 2 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2013 – 2014			
9. Programme Budget (indicative):			
	2013	2014	Total ²
HPV vaccines (US\$)	\$194,500	\$176,500	\$371,000
Cash (\$)	\$170,000	\$25,000	\$195,000
Total Programme Budget (US\$)	\$364,500	\$201,500	\$566,000
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts:³			
<i>Vaccines</i>			
	2013	2014	
Type of supplies to be purchased with GAVI funds in each year	37,813	34,376	
Number of HPV vaccines doses	38,191	34,376	
Number of AD syringes	500	400	
Number of safety boxes	\$194,500	\$176,500	
Annual Amounts (US\$)			
<i>Cash support:</i>			
	2013		
Cash Support by year	\$170,000		
Annual Amounts (US\$)			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.


³ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

DECISION LETTER FOR VACCINE SUPPORT

12. Procurement agency: UNICEF								
13. Self-procurement: Not applicable								
14. Co-financing obligations: Not applicable								
15. Operational support for campaigns: Not applicable								
<p>16. Documents to be delivered for future disbursements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts. Further details can be found in the HPV Guidelines for Applications 2012.</p> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 60%; text-align: center;">Reports, documents and other deliverables</th> <th style="width: 40%; text-align: center;">Due dates</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;"> <ol style="list-style-type: none"> 1. A report of the evaluation of the HPV demonstration programme. 2. A copy of the approval by the local ethics committee, if a country determined that review and approval was required. 3. A report of the feasibility assessment of adolescent health interventions, with conclusions about what interventions are or are not feasible. 4. If an adolescent health intervention is identified for joint delivery with HPV vaccine, a description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved. 5. A summary of the activities completed and progress towards development of a national cervical cancer prevention and control strategy. </td> <td style="padding: 5px; vertical-align: top;">End of first year (the first year starts when the first dose of vaccine is administered)</td> </tr> <tr> <td style="padding: 5px;"> <ol style="list-style-type: none"> 1. Financial reports for the GAVI HPV demonstration programme covering the year ended, in form and substance satisfactory to GAVI. </td> <td style="padding: 5px; vertical-align: top;">Within 3 months of the end of each Country's fiscal year.</td> </tr> <tr> <td style="padding: 5px;"> <ol style="list-style-type: none"> 1. A summary report of year two delivery of HPV vaccinations, if not jointly delivered with adolescent health interventions. 2. If HPV was delivered jointly with adolescent health interventions, based on the year one feasibility assessment, an evaluation report of that delivery is required. 3. A copy of the developed or revised national cervical cancer prevention and control strategy. </td> <td style="padding: 5px; vertical-align: top;">End of second year (the first year starts when the first dose of vaccine is administered and continues for twelve calendar months)</td> </tr> </tbody> </table>	Reports, documents and other deliverables	Due dates	<ol style="list-style-type: none"> 1. A report of the evaluation of the HPV demonstration programme. 2. A copy of the approval by the local ethics committee, if a country determined that review and approval was required. 3. A report of the feasibility assessment of adolescent health interventions, with conclusions about what interventions are or are not feasible. 4. If an adolescent health intervention is identified for joint delivery with HPV vaccine, a description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved. 5. A summary of the activities completed and progress towards development of a national cervical cancer prevention and control strategy. 	End of first year (the first year starts when the first dose of vaccine is administered)	<ol style="list-style-type: none"> 1. Financial reports for the GAVI HPV demonstration programme covering the year ended, in form and substance satisfactory to GAVI. 	Within 3 months of the end of each Country's fiscal year.	<ol style="list-style-type: none"> 1. A summary report of year two delivery of HPV vaccinations, if not jointly delivered with adolescent health interventions. 2. If HPV was delivered jointly with adolescent health interventions, based on the year one feasibility assessment, an evaluation report of that delivery is required. 3. A copy of the developed or revised national cervical cancer prevention and control strategy. 	End of second year (the first year starts when the first dose of vaccine is administered and continues for twelve calendar months)
Reports, documents and other deliverables	Due dates							
<ol style="list-style-type: none"> 1. A report of the evaluation of the HPV demonstration programme. 2. A copy of the approval by the local ethics committee, if a country determined that review and approval was required. 3. A report of the feasibility assessment of adolescent health interventions, with conclusions about what interventions are or are not feasible. 4. If an adolescent health intervention is identified for joint delivery with HPV vaccine, a description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved. 5. A summary of the activities completed and progress towards development of a national cervical cancer prevention and control strategy. 	End of first year (the first year starts when the first dose of vaccine is administered)							
<ol style="list-style-type: none"> 1. Financial reports for the GAVI HPV demonstration programme covering the year ended, in form and substance satisfactory to GAVI. 	Within 3 months of the end of each Country's fiscal year.							
<ol style="list-style-type: none"> 1. A summary report of year two delivery of HPV vaccinations, if not jointly delivered with adolescent health interventions. 2. If HPV was delivered jointly with adolescent health interventions, based on the year one feasibility assessment, an evaluation report of that delivery is required. 3. A copy of the developed or revised national cervical cancer prevention and control strategy. 	End of second year (the first year starts when the first dose of vaccine is administered and continues for twelve calendar months)							
17. Clarifications: Programmatic clarifications already addressed								
<p>18. Conditions:</p> <ol style="list-style-type: none"> 1. Disbursement of HPV funds will be made in 2 tranches. The first tranche will be disbursed for an amount representing approximately the first eighteen months of forecasted programme expenditures. Second tranche to be released upon provision of satisfactory annual financial report only. 2. New external auditor is to be selected based on competitive process and audit is to be performed based on ToR provided by GAVI 3. Country is requested to budget an appropriate audit fee and make available a revised budget to GAVI. 								
<p>19. Other conditions: In year two, GAVI will disburse USD 25,000 for testing of joint delivery of adolescent health services with vaccination only if the country satisfies the following conditions: (i) the report of the feasibility assessment of adolescent health interventions has a conclusion that the interventions are feasible; and (ii) the Country has submitted description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved.</p>								

Signed by

On behalf of the GAVI Alliance



Hind Khatib-Othman

Managing Director, Country Programmes

Date: